Concord Medical Services (NYSE:CCM) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Concord Medical Services (NYSE:CCM) to a hold rating in a research report report published on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Concord Medical Services in a research note on Tuesday, May 26th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Concord Medical Services Stock Performance

Shares of CCM stock opened at $4.72 on Friday. The stock’s fifty day simple moving average is $4.62 and its 200 day simple moving average is $4.28. The company has a quick ratio of 0.46, a current ratio of 0.48 and a debt-to-equity ratio of 1.33. Concord Medical Services has a one year low of $3.18 and a one year high of $6.98.

About Concord Medical Services

Concord Medical Services Holdings Limited is one of China’s leading providers of radiotherapy equipment and oncology services. The company specializes in supplying and operating advanced radiotherapy machines, including linear accelerators, computed tomography (CT) simulators and brachytherapy units, to public and private hospitals. Through its integrated service model, Concord Medical Services delivers treatment planning, machine maintenance and clinical support to enhance the precision and effectiveness of cancer therapies.

Founded in 1997 and headquartered in Beijing, Concord Medical Services has developed an extensive network of oncology centers across major cities and provinces in China.